FinscoFinsco

Caris Life Sciences (US.CAI)

Capital Allocation Audit · Period: 2022 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CAI · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion68.5%↓
ROE-0.1%→
Cash Conversion-→
D/E Ratio0.73→
Gross Margin65.4%↑
US.CAI (Caris Life Sciences) | YoY: 2026 Q1 vs 2025 Q1


Metric           Value  YoY
---------------------------
FCF Conversion   68.5%    ↓
ROE              -0.1%    →
Cash Conversion      -    →
D/E Ratio         0.73    →
Gross Margin     65.4%    ↑
Key Metrics
US.CAI (Caris Life Sciences) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
---------------------------
FCF Conversion 68.5% ↓
ROE -0.1% →
Cash Conversion - →
D/E Ratio 0.73 →
Gross Margin 65.4% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies